Antitrust
RegulationWatch reporting on antitrust matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- Antitrust
Forty-five states seek approval of generic price-fixing settlements with Ascend, Mayne and Citron
A 45-state coalition asked the court to approve settlements with three more generic manufacturers in the long-running price-fixing litigation. The monetary terms total $1.05 million; the larger cases against Teva, Sandoz and others continue.
- Antitrust
States seek approval of Sandoz settlement worth approximately $469 million
State attorneys general sought approval of a generic-drug pricing settlement with Sandoz and Fougera. Illinois described approximately $469 million in total obligations, including $69 million for previously settling states.
- Antitrust
Caremark wins partial dismissal while Rxeed interference claim survives
A New York federal judge dismissed Rxeed's antitrust and contractual-interference claims against Caremark. A claim concerning prospective business relationships remains pending.
- Antitrust
Florida sues Prime Therapeutics and Express Scripts over alleged pharmacy price-fixing
Florida Attorney General James Uthmeier has sued Prime Therapeutics LLC and Express Scripts, Inc., alleging the two pharmacy benefit managers entered a horizontal price-fixing agreement that cut reimbursements to Florida pharmacies. The state seeks injunctive relief, civil penalties, disgorgement and damages.
- Antitrust
Sandoz will pay $450 million to settle generic price-fixing claims and says its outlook is unchanged.
The deal carries no admission. The company had already reserved for it.
- Antitrust
Sandoz agrees $450 million settlement with 43 states over generic drug pricing
Sandoz has agreed to pay about $450 million to resolve antitrust claims brought by 43 US states and territories over alleged price-fixing and market allocation in the generic drug market. The company said the deal contains no admission of wrongdoing and resolves all remaining US government claims against it from the long-running investigation.
